Supernus Pharmaceuticals, Inc. (0LB2.L)
USD 31.68
(1.57%)
USD 31.68
(1.57%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 523.74 Million USD | -24.33% |
| 2022 | 580.01 Million USD | 14.92% |
| 2021 | 504.71 Million USD | 7.86% |
| 2020 | 467.93 Million USD | 24.42% |
| 2019 | 376.09 Million USD | -4.43% |
| 2018 | 393.54 Million USD | 37.11% |
| 2017 | 287.02 Million USD | 41.38% |
| 2016 | 203.01 Million USD | 49.27% |
| 2015 | 136 Million USD | 16.96% |
| 2014 | 116.28 Million USD | 965.39% |
| 2013 | 10.91 Million USD | 637.5% |
| 2012 | 1.48 Million USD | 84.31% |
| 2011 | 803 Thousand USD | -94.06% |
| 2010 | 13.51 Million USD | -70.95% |
| 2009 | 46.51 Million USD | 423.29% |
| 2008 | 8.88 Million USD | 109.96% |
| 2007 | 4.23 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | 138.01 Million USD | 6.41% |
| 2024 Q2 | 129.7 Million USD | 21.69% |
| 2024 Q1 | 106.58 Million USD | -13.35% |
| 2023 Q4 | 123.01 Million USD | -8.39% |
| 2023 Q3 | 134.27 Million USD | 17.3% |
| 2023 Q1 | 130.3 Million USD | -9.75% |
| 2023 Q2 | 114.47 Million USD | -12.15% |
| 2023 FY | 438.88 Million USD | -24.33% |
| 2022 FY | 580.01 Million USD | 14.92% |
| 2022 Q4 | 144.37 Million USD | -4.69% |
| 2022 Q2 | 149.59 Million USD | 11.16% |
| 2022 Q1 | 134.57 Million USD | -5.27% |
| 2022 Q3 | 151.47 Million USD | 1.26% |
| 2021 Q3 | 130.37 Million USD | 12.1% |
| 2021 Q1 | 115.97 Million USD | -7.24% |
| 2021 FY | 504.71 Million USD | 7.86% |
| 2021 Q2 | 116.3 Million USD | 0.28% |
| 2021 Q4 | 142.05 Million USD | 8.96% |
| 2020 Q3 | 133.74 Million USD | 13.02% |
| 2020 Q2 | 118.34 Million USD | 30.3% |
| 2020 Q1 | 90.82 Million USD | -5.72% |
| 2020 FY | 467.93 Million USD | 24.42% |
| 2020 Q4 | 125.02 Million USD | -6.52% |
| 2019 Q1 | 81.79 Million USD | -26.81% |
| 2019 Q3 | 97.32 Million USD | -3.31% |
| 2019 Q2 | 100.65 Million USD | 23.06% |
| 2019 Q4 | 96.33 Million USD | -1.02% |
| 2019 FY | 376.09 Million USD | -4.43% |
| 2018 FY | 393.54 Million USD | 37.11% |
| 2018 Q1 | 87.15 Million USD | 3.41% |
| 2018 Q2 | 95.85 Million USD | 9.99% |
| 2018 Q3 | 98.78 Million USD | 3.06% |
| 2018 Q4 | 111.74 Million USD | 13.12% |
| 2017 Q1 | 54.62 Million USD | -6.78% |
| 2017 Q3 | 76.14 Million USD | 5.81% |
| 2017 Q4 | 84.28 Million USD | 10.68% |
| 2017 FY | 287.02 Million USD | 41.38% |
| 2017 Q2 | 71.96 Million USD | 31.74% |
| 2016 Q3 | 53.38 Million USD | 11.98% |
| 2016 Q2 | 47.67 Million USD | 16.15% |
| 2016 Q1 | 41.04 Million USD | 2.96% |
| 2016 FY | 203.01 Million USD | 49.27% |
| 2016 Q4 | 58.6 Million USD | 9.78% |
| 2015 Q2 | 33.29 Million USD | 25.55% |
| 2015 Q3 | 36.33 Million USD | 9.16% |
| 2015 Q4 | 39.86 Million USD | 9.7% |
| 2015 FY | 136 Million USD | 16.96% |
| 2015 Q1 | 26.51 Million USD | -7.03% |
| 2014 Q4 | 28.51 Million USD | -44.26% |
| 2014 Q3 | 51.16 Million USD | 82.65% |
| 2014 Q2 | 28.01 Million USD | 226.24% |
| 2014 FY | 116.28 Million USD | 965.39% |
| 2014 Q1 | 8.58 Million USD | -7.35% |
| 2013 Q1 | 147 Thousand USD | -86.51% |
| 2013 Q3 | 1.22 Million USD | 341.88% |
| 2013 Q4 | 9.26 Million USD | 657.19% |
| 2013 FY | 10.91 Million USD | 637.5% |
| 2013 Q2 | 277 Thousand USD | 88.44% |
| 2012 Q2 | 91 Thousand USD | -56.25% |
| 2012 Q4 | 1.09 Million USD | 1097.8% |
| 2012 FY | 1.48 Million USD | 84.31% |
| 2012 Q3 | 91 Thousand USD | 0.0% |
| 2012 Q1 | 208 Thousand USD | 102.11% |
| 2011 Q3 | 11 Thousand USD | -98.53% |
| 2011 Q4 | -9.84 Million USD | -89600.0% |
| 2011 FY | 803 Thousand USD | -94.06% |
| 2011 Q2 | 750 Thousand USD | 0.0% |
| 2011 Q1 | - USD | -100.0% |
| 2010 FY | 13.51 Million USD | -70.95% |
| 2010 Q4 | 4.77 Million USD | 0.0% |
| 2009 FY | 46.51 Million USD | 423.29% |
| 2009 Q4 | 3.44 Million USD | 0.0% |
| 2008 FY | 8.88 Million USD | 109.96% |
| 2007 FY | 4.23 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 15.22 Billion USD | 96.56% |
| Dynavax Technologies Corporation | 182.11 Million USD | -187.585% |
| Illumina, Inc. | 2.74 Billion USD | 80.913% |
| IQVIA Holdings Inc. | 5.23 Billion USD | 90.003% |
| Biogen Inc. | 7.3 Billion USD | 92.828% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | 5575.037% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 75.854% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | 52.082% |
| Waters Corporation | 1.76 Billion USD | 70.262% |
| Perrigo Company plc | 1.68 Billion USD | 68.832% |
| uniQure N.V. | 2.21 Million USD | -23545.237% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | -2924.089% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | -44.668% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | 167429.712% |
| bluebird bio, Inc. | -4.03 Million USD | 13096.079% |
| Cara Therapeutics, Inc. | 14.79 Million USD | -3440.233% |
| Imunon, Inc. | -720 Thousand USD | 72841.439% |
| Myriad Genetics, Inc. | 476.4 Million USD | -9.937% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 71.65% |
| Nektar Therapeutics | 53.47 Million USD | -879.36% |
| Editas Medicine, Inc. | -99.52 Million USD | 626.226% |
| Verastem, Inc. | -62 Thousand USD | 844845.161% |
| Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 98.025% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 1780.402% |
| Heron Therapeutics, Inc. | 10.04 Million USD | -5115.515% |
| Unity Biotechnology, Inc. | -19.69 Million USD | 2758.724% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 72.498% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 1255.526% |
| Evolus, Inc. | 140.52 Million USD | -272.701% |
| Adicet Bio, Inc. | -6.09 Million USD | 8688.75% |
| Aclaris Therapeutics, Inc. | -85.21 Million USD | 714.605% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 95.366% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | -616.797% |
| FibroGen, Inc. | 128.9 Million USD | -306.304% |
| Agilent Technologies, Inc. | 3.46 Billion USD | 84.885% |
| OPKO Health, Inc. | 318.12 Million USD | -64.633% |
| Homology Medicines, Inc. | -7.22 Million USD | 7345.013% |
| Geron Corporation | -123.5 Million USD | 524.072% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | 65.495% |
| Exelixis, Inc. | 1.75 Billion USD | 70.202% |
| Viking Therapeutics, Inc. | -292 Thousand USD | 179463.699% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 231.331% |
| Zoetis Inc. | 5.83 Billion USD | 91.023% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | -114.179% |
| Abeona Therapeutics Inc. | 302 Thousand USD | -173324.503% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 93.915% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 172952.145% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | 32.725% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | -10.054% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | 17.766% |
| Blueprint Medicines Corporation | 236.58 Million USD | -121.377% |
| Insmed Incorporated | 239.63 Million USD | -118.558% |
| TG Therapeutics, Inc. | 219.1 Million USD | -139.034% |
| Incyte Corporation | 3.44 Billion USD | 84.778% |
| Emergent BioSolutions Inc. | 343.9 Million USD | -52.295% |